NASDAQ:TNDM - Tandem Diabetes Care Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$25.89 +0.44 (+1.73 %)
(As of 07/16/2018 08:13 AM ET)
Previous Close$25.45
Today's Range$24.59 - $26.20
52-Week Range$2.14 - $26.24
Volume2.11 million shs
Average Volume3.29 million shs
Market Capitalization$1.30 billion
P/E Ratio-2.01
Dividend YieldN/A
Beta-0.15
Tandem Diabetes Care logoTandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TNDM
CUSIPN/A
Phone858-366-6900

Debt

Debt-to-Equity Ratio6.45
Current Ratio2.62
Quick Ratio2.01

Price-To-Earnings

Trailing P/E Ratio-2.01
Forward P/E Ratio-18.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$107.60 million
Price / Sales12.05
Cash FlowN/A
Price / CashN/A
Book Value($2.88) per share
Price / Book-8.99

Profitability

EPS (Most Recent Fiscal Year)($12.87)
Net Income$-73,030,000.00
Net Margins-70.69%
Return on EquityN/A
Return on Assets-63.52%

Miscellaneous

Employees574
Outstanding Shares50,070,000
Market Cap$1,296.26

The Truth About Cryptocurrencies

Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care's stock reverse split on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care Inc (NASDAQ:TNDM) released its quarterly earnings results on Thursday, March, 1st. The medical device company reported ($1.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.11) by $0.13. The medical device company had revenue of $40 million for the quarter, compared to analyst estimates of $38.41 million. The firm's quarterly revenue was up 61.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.48) EPS. View Tandem Diabetes Care's Earnings History.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Tandem Diabetes Care.

What price target have analysts set for TNDM?

9 Wall Street analysts have issued 1 year target prices for Tandem Diabetes Care's stock. Their forecasts range from $3.00 to $30.00. On average, they expect Tandem Diabetes Care's share price to reach $15.4375 in the next year. This suggests that the stock has a possible downside of 40.4%. View Analyst Ratings for Tandem Diabetes Care.

What is the consensus analysts' recommendation for Tandem Diabetes Care?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Tandem Diabetes Care?

Tandem Diabetes Care saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 5,883,644 shares, an increase of 111.5% from the June 15th total of 2,782,413 shares. Based on an average daily volume of 4,761,328 shares, the days-to-cover ratio is presently 1.2 days. Approximately 14.7% of the company's stock are short sold. View Tandem Diabetes Care's Current Options Chain.

Who are some of Tandem Diabetes Care's key competitors?

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the folowing people:
  • Mr. Kim D. Blickenstaff, Pres, CEO & Director (Age 66)
  • Mr. John F. Sheridan, Exec. VP & COO (Age 63)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 50)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 45)
  • Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 39)

Has Tandem Diabetes Care been receiving favorable news coverage?

Media stories about TNDM stock have been trending positive on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.29 on Accern's scale. They also assigned news headlines about the medical device company an impact score of 46.66 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $25.89.

How big of a company is Tandem Diabetes Care?

Tandem Diabetes Care has a market capitalization of $1.30 billion and generates $107.60 million in revenue each year. The medical device company earns $-73,030,000.00 in net income (profit) each year or ($12.87) on an earnings per share basis. Tandem Diabetes Care employs 574 workers across the globe.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]


MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  293 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.